{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:47:07Z","timestamp":1792637227499,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100031688","name":"Pfizer Pharma GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031688","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40121-024-01088-w","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T18:26:26Z","timestamp":1733682386000},"page":"149-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany"],"prefix":"10.1007","volume":"14","author":[{"given":"Timotheus","family":"Stremel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Schnaidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bihrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fr\u00f6ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"key":"1088_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajem.2022.01.028","volume":"54","author":"B Long","year":"2022","unstructured":"Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med. 2022;54:46\u201357.","journal-title":"Am J Emerg Med"},{"key":"1088_CR2","volume":"370","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for COVID-19. BMJ (Clin Res Edn). 2020;370: m3379.","journal-title":"BMJ (Clin Res Edn)"},{"key":"1088_CR3","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) onine. S3-Leitlinie Empfehlungen zur Therapie von Patienten mit COVID-19\u2014living guideline. Version 10; 2024. Available from https:\/\/register.awmf.org\/de\/leitlinien\/detail\/113-001. Accessed 25 Nov 2022."},{"key":"1088_CR4","unstructured":"Intensivregister-Team am RKI. Tagesreport aus dem DIVI-Intensivregister (Stand 01.01.2022); 2022. Available from https:\/\/edoc.rki.de\/bitstream\/handle\/176904\/9195\/2022-01-01_12-15_DIVI_Intensivregister_Report.pdf?sequence=1&isAllowed=y. Accessed 25 Nov 2022."},{"issue":"12","key":"1088_CR5","first-page":"1663","volume":"26","author":"I Nachtigall","year":"2020","unstructured":"Nachtigall I, Lenga P, J\u00f3\u017awiak K, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Inf Off Publ Eur Soc Clin Microbiol Infect Dis. 2020;26(12):1663\u20139.","journal-title":"Clin Microbiol Inf Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"1088_CR6","unstructured":"European Medicines Agency (EMA). Paxlovid; 2022 Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid."},{"issue":"13","key":"1088_CR7","first-page":"1290","volume":"328","author":"K Hansen","year":"2023","unstructured":"Hansen K, Makkar SR, Sahner D, Fessel J, Hotaling N, Sidky H. Paxlovid (nirmatrelvir\/ritonavir) effectiveness against hospitalization and death in N3C: a target trial emulation study. medRxiv. 2023;328(13):1290.","journal-title":"medRxiv"},{"key":"1088_CR8","unstructured":"Pfizer. EPIC-HR: study of oral PF-07321332\/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 U.S. National Library of Medicine 2021; 2023. Available from https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT04960202."},{"key":"1088_CR9","unstructured":"Pfizer. Clinical studies. Efficacy in subjects at high risk of progression to severe COVID-19 (EPIC-HR); 2023 [cited February 2, 2024]. Available from https:\/\/www.paxlovidhcp.com\/clinical-studies."},{"key":"1088_CR10","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.5888\/pcd18.210123","volume":"18","author":"L Kompaniyets","year":"2021","unstructured":"Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021. Prev Chronic Dis. 2021;18:E66.","journal-title":"Prev Chronic Dis"},{"key":"1088_CR11","unstructured":"University of Liverpool. Interactions with essential medicines & nirmatrelvir\/ritonavir (NMV\/r) (as of September 16, 2022); 2022. Available from https:\/\/covid19-druginteractions.org\/checker. Accessed 25 Nov 2022."},{"key":"1088_CR12","unstructured":"University of Liverpool. Interactions with outpatient medicines & nirmatrelvir\/ritonavir (NMV\/r) (as of September 27, 2022); 2022. Available from https:\/\/covid19-druginteractions.org\/checker. Accessed 25 Nov 2022."},{"key":"1088_CR13","unstructured":"Robert Koch-Institut. Anzahl und Anteile von VOC und VOI in Deutschland; 2023 [cited February 10, 2023]. Available from https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Daten\/VOC_VOI_Tabelle.html."},{"key":"1088_CR14","unstructured":"Verband der Ersatzkassen e. V. (vdek). vdek-Basisdaten des Gesundheitswesens in Deutschland. GKV - Anzahl der gesetzlichen Krankenkassen. Konzentrationsprozess durch Fusionen. 1970-2024\/01; 2024 [cited September 9, 2024]. Available from https:\/\/www.vdek.com\/presse\/daten\/_jcr_content\/par\/publicationelement_1479644990\/file.res\/vdek_basisdaten_2024.pdf."},{"issue":"1","key":"1088_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25(1):106\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1088_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362.","journal-title":"Public Health"},{"key":"1088_CR17","unstructured":"Statistisches Bundesamt DESTATIS. Bev\u00f6lkerung nach Nationalit\u00e4t und Geschlecht (Quartalszahlen); 2021. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/liste-zensus-geschlecht-staatsangehoerigkeit.html. Accessed 25 Nov 2022."},{"key":"1088_CR18","unstructured":"Bundesministerium f\u00fcr Gesundheit. Gesetzliche Krankenversicherung: Mitglieder, mitversicherte Angeh\u00f6rige und Krankenstand-Jahresdurchschnitt 2021; 2022. Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_JD_2021_K_bf.pdf. Accessed 25 Nov 2022."},{"key":"1088_CR19","unstructured":"Robert Koch-Institut. Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19. 15. Risikogruppen f\u00fcr schwere Verl\u00e4ufe. (Stand 26.11.2021) 2021. Available from: https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Steckbrief.html?nn=13490888#doc13776792bodyText15. Accessed 25 Nov 2022."},{"issue":"1","key":"1088_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s15010-021-01645-2","volume":"50","author":"JJ Malin","year":"2022","unstructured":"Malin JJ, Spinner CD, Janssens U, et al. Key summary of German national treatment guidance for hospitalized COVID-19 patients\u202f: key pharmacologic recommendations from a national German living guideline using an evidence to decision framework (last updated 17.05.2021). Infect. 2022;50(1):93\u2013106.","journal-title":"Infect"},{"issue":"37","key":"1088_CR21","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","volume":"71","author":"S Adjei","year":"2022","unstructured":"Adjei S, Hong K, Molinari NM, et al. Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods\u2014United States, April 2020\u2013June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1182\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1088_CR22","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). Fachinformation zu Paxlovid\u00ae (Nirmatrelvir + Ritonavir) f\u00fcr Angeh\u00f6rige der medizinischen Fachkreise (Stand Oktober 2022); 2022. Available from https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Zulassung\/paxlovid-fachinformation-fachkreise.html. Accessed 25 Nov 2022."},{"issue":"1","key":"1088_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-019-0837-x","volume":"18","author":"P Bramlage","year":"2019","unstructured":"Bramlage P, Lanzinger S, van Mark G, et al. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Cardiovasc Diabetol. 2019;18(1):33.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1088_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2015-000135","volume":"3","author":"Y Du","year":"2015","unstructured":"Du Y, Heidemann C, Schaffrath Rosario A, et al. Changes in diabetes care indicators: findings from German National Health Interview and examination surveys 1997\u20131999 and 2008\u20132011. BMJ Open Diabetes Res Care. 2015;3(1): e000135.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"Suppl 2","key":"1088_CR25","first-page":"2","volume":"6","author":"A Rommel","year":"2021","unstructured":"Rommel A, von der Lippe E, Treskova-Schwarzbach M, Scholz S. Population with an increased risk of severe COVID-19 in Germany analyses from GEDA 2019\/2020-EHIS. J Health Monitor. 2021;6(Suppl 2):2\u201315.","journal-title":"J Health Monitor"},{"key":"1088_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2023.04.014","volume":"138","author":"L Bechmann","year":"2023","unstructured":"Bechmann L, Esser T, F\u00e4rber J, Kaasch A, Geginat G. Outcomes of influenza and COVID-19 inpatients in different phases of the SARS-CoV-2 pandemic: a single-centre retrospective case-control study. J Hosp Infect. 2023;138:1\u20137.","journal-title":"J Hosp Infect"},{"issue":"1","key":"1088_CR27","first-page":"856","volume":"17","author":"Y Alimohamadi","year":"2022","unstructured":"Alimohamadi Y, Yekta EM, Sepandi M, Sharafoddin M, Arshadi M, Hesari E. Hospital length of stay for COVID-19 patients: a systematic review and meta-analysis. Multidiscip Respir Med. 2022;17(1):856.","journal-title":"Multidiscip Respir Med"},{"issue":"9","key":"1088_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283651","volume":"18","author":"K Gholipour","year":"2023","unstructured":"Gholipour K, Behpaie S, Iezadi S, Ghiasi A, Tabrizi JS. Costs of inpatient care and out-of-pocket payments for COVID-19 patients: a systematic review. PLoS ONE. 2023;18(9): e0283651.","journal-title":"PLoS ONE"},{"issue":"1","key":"1088_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50145","volume":"7","author":"KA Kapinos","year":"2024","unstructured":"Kapinos KA, Peters RM Jr, Murphy RE, Hohmann SF, Podichetty A, Greenberg RS. Inpatient costs of treating patients with COVID-19. JAMA Netw Open. 2024;7(1): e2350145.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1088_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13561-023-00476-1","volume":"14","author":"LR Zwerwer","year":"2024","unstructured":"Zwerwer LR, Kloka J, van der Pol S, et al. Mechanical ventilation as a major driver of COVID-19 hospitalization costs: a costing study in a German setting. Heal Econ Rev. 2024;14(1):4.","journal-title":"Heal Econ Rev"},{"key":"1088_CR31","unstructured":"European Medicines Agency (EMA). ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2; 2022 [cited September 27, 2024]. Available from https:\/\/www.ema.europa.eu\/en\/news\/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2."},{"issue":"1","key":"1088_CR32","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41467-024-47393-3","volume":"15","author":"C Liu","year":"2024","unstructured":"Liu C, Das R, Dijokaite-Guraliuc A, et al. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4\/5 infection. Nat Commun. 2024;15(1):3284.","journal-title":"Nat Commun"},{"issue":"2","key":"1088_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jval.2023.11.003","volume":"27","author":"J Carlson","year":"2024","unstructured":"Carlson J, Foos V, Kasle A, et al. Cost-effectiveness of oral nirmatrelvir\/ritonavir in patients at high risk for progression to severe COVID-19 in the United States. Value Health J Int Soc Pharmacoecon Outcomes Res. 2024;27(2):164\u201372.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"12","key":"1088_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.18553\/jmcp.2023.29.12.1290","volume":"29","author":"R Sandin","year":"2023","unstructured":"Sandin R, Veenstra DL, Vankelegom M, et al. Budget impact of oral nirmatrelvir\/ritonavir in adults at high risk for progression to severe COVID-19 in the United States. J Manage Care Spec Pharm. 2023;29(12):1290\u2013302.","journal-title":"J Manage Care Spec Pharm"},{"issue":"1","key":"1088_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40121-023-00910-1","volume":"13","author":"HJ Appaneal","year":"2024","unstructured":"Appaneal HJ, LaPlante KL, Lopes VV, et al. Nirmatrelvir\/ritonavir utilization for the treatment of non-hospitalized adults with COVID-19 in the national veterans affairs (VA) healthcare system. Infect Dis Ther. 2024;13(1):155\u201372.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1088_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/v15010175","volume":"15","author":"L Zsichla","year":"2023","unstructured":"Zsichla L, M\u00fcller V. Risk factors of severe COVID-19: a review of host, viral and environmental factors. Viruses. 2023;15(1):175.","journal-title":"Viruses"},{"issue":"1","key":"1088_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","volume":"71","author":"C Yek","year":"2022","unstructured":"Yek C, Warner S, Wiltz JL, et al. Risk factors for severe COVID-19 outcomes among persons aged \u226518 years who completed a primary COVID-19 vaccination series\u2014465 health care facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022;71(1):19\u201325.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1088_CR38","unstructured":"University of Liverpool. Interactions with Essential Medicines & Nirmatrelvir\/ritonavir (NMV\/r) (as of May 31, 2023); 2023 [cited April 10, 2024]. Available from www.covid19-druginteractions.org\/prescribing_resources\/paxlovid-essential-medicines."},{"issue":"9","key":"1088_CR39","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/biology12091267","volume":"12","author":"M Andre","year":"2023","unstructured":"Andre M, Lau LS, Pokharel MD, et al. From alpha to omicron: how different variants of concern of the SARS-Coronavirus-2 impacted the world. Biology. 2023;12(9):1267.","journal-title":"Biology"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01088-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01088-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01088-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:58:56Z","timestamp":1738216736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01088-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01088-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,8]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Agnes Kisser and Emma Fr\u00f6ling are full-time employees of Pfizer Pharma GmbH. Nicole Bihrer was an employee of Pfizer Pharma GmbH at the time of the study and completion of the manuscript, but not at the time of publication. Christian Jacob, Timotheus Stremel, and Svitlana Schnaidt are a full-time employee of Xcenda GmbH, part of Cencora Inc., acting as contractors of Pfizer Pharma GmbH for the execution of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Claims data from the participating SHIs are joined in a specialized trust center, anonymized, and transferred to InGef before the data are made available for research. The analysis of claims data from the SHI is fully compliant with German federal law and in accordance with the \u201cGPS\u2014Good Practice in Secondary Data Analysis\u201d (Guideline 1: Ethics), the approval of an ethics committee and informed consent of the patients were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}